Vitality Watch

Dossier pubmed preclinical 08-jun-2026
Animal model, organoid, or cell-culture result — not yet human

ACAT3 controls hepatic cholesterol metabolism and modulates systemic energy homeostasis of male mice.

Key claim: Hepatic ACAT3 regulates cholesterol and bile-acid pathways that reshape gut microbiota and systemic energy homeostasis in male mice, and its expression is downregulated with obesity, diabetes, and aging.

Abstract

AIMS: Acetyl coenzyme A acetyltransferase (ACAT) family enzymes catalyses the conversion of acetyl-CoA into acetoacetyl-CoA that provides the substrate for ketone and cholesterol biosynthesis. In the present study, we aimed to assess the function of hepatic ACAT3 in cholesterol and bile acid homeostasis, and its effects on systemic energy metabolism. MATERIALS AND METHODS: We used genetic overexpression and knockout (KO) mouse models to liver-targeted access the function of ACAT3 in mouse liver. We then applied multiple analysis to investigate the changes in morphology, physiology, histology and molecular levels of the mice. KEY FINDINGS: Acat3 is highly expressed in liver tissue of mice and its expression levels are downregulated during obesity, diabetes and aging. Hepatic Acat3 overexpression reduces body weight, fat mass and promotes glucose metabolism in mice. Mice with Acat3 overexpression have reduced serum lipid concentrations and adipose tissue weight. While Acat3 overexpression changed hepatic Cholesterol metabolic signaling and bile acid composition. Global and liver-specific (Acat3) Acat3 KO mice have reduced lean mass and energy expenditure. Liver-specific Acat3 KO reduces body weight, disrupts the gut microbiota and hepatic bile acid composition. SIGNIFICANCE: Both overexpression and knockout of Acat3 lead to changes in hepatic cholesterol metabolic pathway, which alters bile acid synthesis and composition. These alterations in bile acid profiles subsequently influence intestinal microbiota, thereby modulating systemic energy homeostasis of mice. Modulation of ACAT3 or its downstream mechanisms alters bile acid profiles to improve glucose and lipid metabolism and develop new therapeutic strategies for clinical applications.

Why this matters

Most gut–liver–bile-acid aging work has emphasized microbial enzymes (BSH, 7α-dehydroxylase) as the modulators of the bile-acid pool; ACAT3 nominates a liver-intrinsic cholesterol-esterifying gene whose age-linked decline could shift bile-acid output before microbes act on it. That reframes part of the age-related dysbiosis signal as potentially downstream of hepatic cholesterol handling rather than primarily microbial. Evidence is a single male-mouse genetic characterization with no human data and no female-mouse replication.

Source

Link

Briefing card

ACAT3 controls hepatic cholesterol metabolism and modulates systemic energy homeostasis of male mice.
Stage: preclinical · pubmed · 08-jun-2026

Applies to preclinical researchers mapping liver-bile-acid-microbiome pathways in metabolic aging; no human or intervention consequence.

Hepatic ACAT3 regulates cholesterol and bile-acid pathways that reshape gut microbiota and systemic energy homeostasis in male mice, and its expression is downregulated with obesity, diabetes, and aging.

Cross-references (0)

None recorded — doctrine links and citations appear here as scans and citation sweeps find them.

External: doi:10.1016/j.lfs.2026.124519

build build 880 · 2bcef25 · 2026-11-18